COMPANY

Ridgeline Therapeutics

HQ: Houston, TX source · ridgelinetherapeutics.com ↗ · Southwest

Keywords: metabolic musculoskeletal metabolic diseases

Location: Houston, TX · source · Oct 15, 2026

Profile checked Oct 10, 2026

9NIH grants

Funding and NIH signals

NIH award NIH awarded $2.12M (SBIR Phase II 1R44AG102216-01, new, notice Sep 17, 2026); 2 NIH awards totaling $3.02M in the last 12 months. NIH RePORTER 1R44AG102216-01 (Sep 17, 2026)
Evidence (2 events)
- Sep 17, 2026 · NIH RePORTER 1R44AG102216-01
  Organization: RIDGELINE THERAPEUTICS, INC.; City/State: Houston, TX; Project number: 1R44AG102216-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 2117233; Administering IC: National Institute on Aging; Project title: Cardiovascular Safety and Scalable Manufacturing for Investigational New Drug Filing of a Novel Oral Drug to Accelerate Musculoskeletal Recovery in Older Adults; Organization type: Domestic For-Profits
- Jul 28, 2026 · NIH RePORTER 5R44AG092210-02
  Organization: RIDGELINE THERAPEUTICS, INC.; City/State: Houston, TX; Project number: 5R44AG092210-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 904811; Administering IC: National Institute on Aging; Project title: Preclinical validation of a novel adjunct small molecule drug to prevent muscle loss and enhance weight loss in older adults; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 17, 2026 Grant Government grant — SBIR: $2.12M (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Jul 28, 2026 Grant Government grant — SBIR: $904,811 (annual award, as published), announced Jul 28, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Sep 19, 2025 Grant Government grant — SBIR: $1.34M (annual award, as published), announced Sep 19, 2025. Agency: NIH/NIA. Source: government award database. source ↗
Jul 1, 2025 Grant Government grant: $498,988 (total, as published), announced Jul 1, 2025. Agency: DoD. Source: government award database. source ↗

Funding

Last 2 years.

Sep 17, 2026 Government grant — SBIR: $2.12M (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Jul 28, 2026 Government grant — SBIR: $904,811 (annual award, as published), announced Jul 28, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Sep 19, 2025 Government grant — SBIR: $1.34M (annual award, as published), announced Sep 19, 2025. Agency: NIH/NIA. Source: government award database. source ↗
Jul 1, 2025 Government grant: $498,988 (total, as published), announced Jul 1, 2025. Agency: DoD. Source: government award database. source ↗

NIH awards 9

Annual award amounts. Total $5.4M.

Jun 25, 2024 NIH award 3U44AG074107-03S1 FY2024: $236,538 awarded for that fiscal year; activity U44 (SBIR); PI NEELAKANTAN, HARSHINI; recipient as written: RIDGELINE THERAPEUTICS, INC., Houston, TX. Preclinical Development of a source ↗
Aug 23, 2023 NIH award 1R43AG084460-01A1 FY2023: $322,432 awarded for that fiscal year; activity R43 (SBIR); PI WILEY, ANDREA LEAH; recipient as written: RIDGELINE THERAPEUTICS, INC., Houston, TX. A Novel Small Molecule Oral Ther source ↗
Aug 1, 2023 NIH award 5U44AG074107-03 FY2023: $1,242,959 awarded for that fiscal year; activity U44 (SBIR); PI NEELAKANTAN, HARSHINI; recipient as written: RIDGELINE THERAPEUTICS, INC., Houston, TX. Preclinical Development of a source ↗
May 26, 2023 NIH award 3U44AG074107-02S1 FY2023: $247,436 awarded for that fiscal year; activity U44 (SBIR); PI NEELAKANTAN, HARSHINI; recipient as written: RIDGELINE THERAPEUTICS, INC., Houston, TX. Preclinical Development of a source ↗
Sep 2, 2022 NIH award 5U44AG074107-02 FY2022: $1,246,866 awarded for that fiscal year; activity U44 (SBIR); PI NEELAKANTAN, HARSHINI; recipient as written: RIDGELINE THERAPEUTICS, INC., Houston, TX. Preclinical Development of a source ↗
Sep 20, 2021 NIH award 1U44AG074107-01 FY2021: $1,229,027 awarded for that fiscal year; activity U44 (SBIR); PI NEELAKANTAN, HARSHINI; recipient as written: RIDGELINE THERAPEUTICS, INC., Houston, TX. Preclinical Development of a source ↗
Sep 16, 2019 NIH award 1R41AR076871-01 FY2019: $252,131 awarded for that fiscal year; activity R41 (STTR); PI NEELAKANTAN, HARSHINI; recipient as written: RIDGELINE THERAPEUTICS, INC., Houston, TX. Preclinical studies to validate source ↗
Sep 18, 2018 NIH award 1R41AG061989-01 FY2018: $357,630 awarded for that fiscal year; activity R41 (STTR); PI WATOWICH, STANLEY; recipient as written: RIDGELINE THERAPEUTICS, INC., Houston, TX. Dose-ranging safety and efficacy st source ↗
Aug 21, 2018 NIH award 1R41DK119052-01 FY2018: $299,972 awarded for that fiscal year; activity R41 (STTR); PI WATOWICH, STANLEY; recipient as written: RIDGELINE THERAPEUTICS, INC., Houston, TX. Dose-ranging safety and efficacy st source ↗